Quick Answer
CRISPR Therapeutics AG reported Total Assets of $2.27 billion for the year ending 2025.
- CRISPR Therapeutics AG showed an increase of +1.0% in Total Assets from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $278.65 million | Q1 2017: $322.35 million | Q2 2017: $304.98 million | Q3 2017: $282.32 million | Q1 2018: $374.45 million | Q2 2018: $353.13 million | Q3 2018: $518.90 million | Q1 2019: $497.87 million | Q2 2019: $494.25 million | Q3 2019: $720.59 million | Q1 2020: $1.01 billion | Q2 2020: $1.05 billion | Q3 2020: $1.49 billion | Q1 2021: $1.96 billion | Q2 2021: $2.90 billion | Q3 2021: $2.82 billion | Q1 2022: $2.61 billion | Q2 2022: $2.46 billion | Q3 2022: $2.35 billion | Q1 2023: $2.24 billion | Q2 2023: $2.20 billion | Q3 2023: $2.09 billion | Q1 2024: $2.44 billion | Q2 2024: $2.34 billion | Q3 2024: $2.26 billion | Q1 2025: $2.17 billion | Q2 2025: $2.03 billion | Q3 2025: $2.25 billion.
- Over the full 11 years of available data (2015 to 2025), CRISPR Therapeutics AG's Total Assets has grown by 1,320.9%.
- Historical annual values: Fiscal year 2025: $2.27 billion | Fiscal year 2024: $2.24 billion | Fiscal year 2023: $2.23 billion | Fiscal year 2022: $2.24 billion | Fiscal year 2021: $2.75 billion | Fiscal year 2020: $1.83 billion | Fiscal year 2019: $1.07 billion | Fiscal year 2018: $489.02 million | Fiscal year 2017: $271.35 million | Fiscal year 2016: $344.96 million | Fiscal year 2015: $159.42 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: